Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05652816
Other study ID # KET-866/ETIK/2021
Secondary ID
Status Recruiting
Phase Early Phase 1
First received
Last updated
Start date September 6, 2022
Est. completion date December 31, 2024

Study information

Verified date December 2022
Source Indonesia University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to test whether artificial skin graft can substitute autologous skin graft in current burn treatment. The main question it aims to answer is: • Can artificial skin graft result in better wound healing compared to the current burn treatment; autologous skin graft? You will: - Undergo debridement surgery - Receive artificial skin graft as an alternative to autologous skin graft - Undergo biopsy procedure of burn area If there is a comparison group: Researchers will compare autologous skin graft group to see the wound healing process


Description:

Burn caused by working accidents occurs mostly in the male population of productive age (68.68%). Up to this date, the only treatment for grade 2B-3 burns patients in Indonesia is skin transplantation taken from their own body (autologous skin graft). This treatment has several drawbacks in which repeated surgery is sometimes necessary, the source of skin in patients with wide area of burn is limited, and patients that are in the elder age and have comorbidities have high mortality risk. In order to find an alternative for autologous skin graft therapy, a combination of tissue engineering and stem cell therapy is used to invent an artificial skin graft. The present study attempts to evaluate the efficacy of artificial skin graft seeded with autologous keratinocyte and stem cells towards wound healing in burn patients. The artificial graft used in this study is amnion bilayer; a graft that was decellularized to remove donor's cells and then layered to form into 3-D. To evaluate the efficacy, biopsies are taken from the burn area of patients to evaluate the histoarchitecture of patients' tissue by histological staining (H&E and Movat's pentachrome, IHC collagen I, collagen III, vWF, and alpha-SMA) and measure the relative gene expression by qPCR. For clinical data, burn area calculation using Rule of 9 method and thermography measurement using FLIRONE. Furthermore, systemic evaluation of patients are done by monitoring the procalcitonin, lactate, mean arterial pressure, gradation of wound, and sensory of burn area. The evaluation and measurement mentioned above are then compared to patients treated with the current available therapy; autologous skin graft. The artificial skin graft is hoped to result in equal, if not better, wound healing in burn patients compared to autologous skin graft. The investigators hope that artificial skin graft can be an option, other than autologous skin graft, in treating burn patients in the future.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date December 31, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Aged 18 - 55 - Area of burn <50% - Acute phase burn (<120 hrs) - Have not undergo any surgery for burn treatment Exclusion Criteria: - Immunocompromised - Have comorbidities

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Split-thickness skin graft
Transplantation of autologous skin to burn area
Biological:
Artificial skin graft
Decellularized amnion membrane formed into 3-D matrix
Artificial skin graft co-culture
Decellularized amnion membrane formed into 3-D matrix seeded with autologous keratinocyte co-cultured with amnion epithelial stem cells

Locations

Country Name City State
Indonesia RSUPN Cipto Mangunkusumo Jakarta Pusat DKI Jakarta

Sponsors (1)

Lead Sponsor Collaborator
Indonesia University

Country where clinical trial is conducted

Indonesia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Burn thickness Thickness of burn evaluation using Rule of 9 Day of surgery
Primary Burn thickness Thickness of burn evaluation using Rule of 9 Day 7 after surgery
Primary Burn thickness Thickness of burn evaluation using Rule of 9 Day 14 after surgery
Primary Burn thermography Thermography evaluation using FLIRONE Day of surgery
Primary Burn thermography Thermography evaluation using FLIRONE Day 7 after surgery
Primary Burn thermography Thermography evaluation using FLIRONE Day 14 after surgery
Primary Systemic clinical evaluation Mean arterial pressure measurement Day of surgery
Primary Systemic clinical evaluation Mean arterial pressure measurement Day 7 after surgery
Primary Systemic clinical evaluation Mean arterial pressure measurement Day 14 after surgery
Primary Systemic clinical evaluation lactate measurement Day of surgery
Primary Systemic clinical evaluation lactate measurement Day 7 after surgery
Primary Systemic clinical evaluation lactate measurement Day 14 after surgery
Primary Systemic clinical evaluation procalcitonin measurement Day of surgery
Primary Systemic clinical evaluation procalcitonin measurement Day 7 after surgery
Primary Systemic clinical evaluation procalcitonin measurement Day 14 after surgery
Primary Systemic clinical evaluation urine excretion rate measurement Day of surgery
Primary Systemic clinical evaluation urine excretion rate measurement Day 7 after surgery
Primary Systemic clinical evaluation urine excretion rate measurement Day 14 after surgery
Primary Histoarchitecture evaluation Haematoxylin & Eosin staining Day of surgery
Primary Histoarchitecture evaluation Haematoxylin & Eosin staining Day 14 after surgery
Primary Histoarchitecture evaluation Movat's Pentachrome staining Day of surgery
Primary Histoarchitecture evaluation Movat's Pentachrome staining Day 14 after surgery
Primary Immunohistochemistry collagen-1 labelling Day of surgery
Primary Immunohistochemistry collagen-1 labelling Day 14 after surgery
Primary Immunohistochemistry collagen-3 labelling Day of surgery
Primary Immunohistochemistry collagen-3 labelling Day 14 after surgery
Primary Immunohistochemistry von Willebrand labelling Day of surgery
Primary Immunohistochemistry von Willebrand labelling Day 14 after surgery
Primary Immunohistochemistry alpha-Smooth Muscle Actin labelling Day of surgery
Primary Immunohistochemistry alpha-Smooth Muscle Actin labelling Day 14 after surgery
Primary Wound healing relative gene expression TGFB1 Day of surgery
Primary Wound healing relative gene expression TGFB1 Day 14 after surgery
Primary Wound healing relative gene expression TGFB3 Day of surgery
Primary Wound healing relative gene expression TGFB3 Day 14 after surgery
Primary Wound healing relative gene expression Wnt4 Day of surgery
Primary Wound healing relative gene expression Wnt4 Day 14 after surgery
Primary Wound healing relative gene expression CTNNB1 Day of surgery
Primary Wound healing relative gene expression CTNNB1 Day 14 after surgery
Primary Wound healing relative gene expression MMP2 Day of surgery
Primary Wound healing relative gene expression MMP2 Day 14 after surgery
Primary Wound healing relative gene expression MMP9 Day of surgery
Primary Wound healing relative gene expression MMP9 Day 14 after surgery
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06440239 - A Study to Evaluate the Safety, Tolerability and Efficacy in Patients With Burn(s) Phase 1/Phase 2
Recruiting NCT06223269 - Safety and Efficacy of realSKIN® to Provide Complete Wound Closure of Burn Wounds as an Alternative to Autografting Phase 3
Recruiting NCT04685577 - Safety, Tolerability and Efficacy of Nefopam Cream in Burn Patients Phase 2
Completed NCT05612867 - Low Dose Vitamin C in Burns >20% Compared to Previous Studies With High Dose Vitamin C
Completed NCT04772573 - The Treatment Challenges and Limitation in High-Voltage Pediatric Electrical Burn at Rural Area
Completed NCT04200053 - The Effect of Reflexology Massage and Passive Music Therapy Intervention Before Burn Dressing N/A